ADAM-8, a metalloproteinase, drives acute allergen-induced airway inflammation

Laboratory of Tumor and Development Biology, GIGA-Research (GIGA-I3 and GIGA-cancer), University of Liege and CHU of Liege, Sart-Tilman, Belgium.
European Journal of Immunology (Impact Factor: 4.03). 02/2011; 41(2):380-91. DOI: 10.1002/eji.200940286
Source: PubMed


Asthma is a complex disease linked to various pathophysiological events including the activity of proteinases. The multifunctional A disintegrin and metalloproteinases (ADAMs) displaying the ability to cleave membrane-bound mediators or cytokines appear to be key mediators in various inflammatory processes. In the present study, we investigated ADAM-8 expression and production in a mouse model of allergen-induced airway inflammation. In allergen-exposed animals, increased expression of ADAM-8 was found in the lung parenchyma and in DC purified from the lungs. The potential role of ADAM-8 in the development of allergen-induced airway inflammation was further investigated by the use of an anti-ADAM-8 antibody and ADAM-8 knockout animals. We observed a decrease in allergen-induced acute inflammation both in BALF and the peribronchial area in anti-ADAM-8 antibody-treated mice and in ADAM-8-deficient mice (ADAM-8(-/-) ) after allergen exposure. ADAM-8 depletion led to a significant decrease of the CD11c(+) lung DC. We also report lower levels of CCL11 and CCL22 production in antibody-treated mice and ADAM-8- deficient mice that might be explained by decreased eosinophilic inflammation and lower numbers of DC, respectively. In conclusion, ADAM-8 appears to favour allergen-induced acute airway inflammation by promoting DC recruitment and CCL11 and CCL22 production.

Download full-text


Available from: Sandrine Bekaert,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Leukocyte recruitment to sites of inflammation proceeds in a cascade-like fashion. However, it is less clear how the complex interactions among the different adhesion molecules involved in this process are coordinately regulated. A report in this issue of the European Journal of Immunology [Eur. J. Immunol. 2011. 41: 3436-3442] shows that ADAM8 may participate in the control of the adhesion molecule P-selectin glycoprotein ligand 1. This finding suggests a new role for ADAM8 in the regulation of inflammatory processes.
    European Journal of Immunology 12/2011; 41(12):3419-22. DOI:10.1002/eji.201142196 · 4.03 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ectoenzymes are a diverse group of membrane proteins that have their catalytic sites outside the plasma membrane. Many of them are found on leukocytes and endothelial cells, and they are multifunctional in nature. Collectively, different ectoenzymes can modulate each step of leukocyte-endothelial contacts, as well as subsequent cell migration in tissues. Here, we review how ectoenzymes belonging to the oxidase, NAD-metabolizing enzyme, nucleotidase and peptidase/protease families regulate and fine-tune leukocyte trafficking, and how ectoenzymes have been targeted both in preclinical and clinical trials.
    European Journal of Immunology 02/2012; 42(2):284-92. DOI:10.1002/eji.201142223 · 4.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rationale: Interleukin-13 (IL-13) is a prototypic Th2 cytokine and a central mediator of the complex cascade of events leading to asthmatic phenotype. Indeed, IL-13 plays key roles in IgE synthesis, bronchial hyperresponsiveness, mucus hypersecretion, subepithelial fibrosis and eosinophil infiltration. Objectives: We assessed the potential efficacy of inhaled anti-IL-13 monoclonal antibody Fab' fragment on allergen-induced airway inflammation, hyperresponsiveness and remodeling in an experimental model of allergic asthma. Anti-IL-13 Fab' was administered to mice as a liquid aerosol generated by inExpose® inhalation system in a tower allowing a nose-only exposure. Methods: BALB/c mice were treated by PBS, anti-IL-13 Fab' or A33 Fab' fragment and subjected to ovalbumin (OVA) exposure for 1 and 5 weeks (short term (ST) and long term (LT) protocols). Measurements and Main Results: Our data demonstrate a significant anti-asthma effect following nebulization of anti-IL-13 Fab' in a model of asthma driven by allergen exposure as compared to saline and non-immune Fab fragments. In short and long terms protocols, administration of the anti-IL-13 Fab' by inhalation significantly decreased bronchial responsiveness to methacholine, BALF eosinophilia, inflammatory cell infiltration in lung tissue, and many features of airway remodeling. Levels of pro-inflammatory mediators and matrix metalloprotease levels were significantly lower in lung parenchyma of mice treated with anti-IL-13 Fab'. Conclusions: These data demonstrate that an inhaled anti-IL-13 Fab' significantly reduces airway inflammation, hyperresponsiveness and remodeling. Specific neutralization of IL-13 in the lungs using an inhaled anti-IL-13 Fab' could represent a novel and effective therapy for the treatment of asthma.
    American Journal of Respiratory Cell and Molecular Biology 08/2012; 47(5). DOI:10.1165/rcmb.2012-0031OC · 3.99 Impact Factor
Show more